Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery

Adv Drug Deliv Rev. 2021 Sep:176:113837. doi: 10.1016/j.addr.2021.113837. Epub 2021 Jun 16.

Abstract

Compared to chemicals that continue to dominate the overall pharmaceutical market, protein therapeutics offer the advantages of higher specificity, greater activity, and reduced toxicity. While nearly all existing therapeutic proteins were developed against soluble or extracellular targets, the ability for proteins to enter cells and target intracellular compartments can significantly broaden their utility for a myriad of exiting targets. Given their physical, chemical, biological instability that could induce adverse effects, and their limited ability to cross cell membranes, delivery systems are required to fully reveal their biological potential. In this context, as natural protein nanocarriers, extracellular vesicles (EVs) hold great promise. Nevertheless, if not present naturally, bringing an interest protein into EV is not an easy task. In this review, we will explore methods used to load extrinsic protein into EVs and compare these natural vectors to their close synthetic counterparts, liposomes/lipid nanoparticles, to induce intracellular protein delivery.

Keywords: Cytoplasmic delivery; Exosomes; Liposomes; Macromolecules delivery; Microvesicles; Therapeutic proteins; Vectorisation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems
  • Extracellular Vesicles / metabolism*
  • Humans
  • Liposomes*
  • Nanoparticles*
  • Proteins / administration & dosage*
  • Proteins / adverse effects
  • Proteins / metabolism

Substances

  • Lipid Nanoparticles
  • Liposomes
  • Proteins